Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $71.00 Price Target at Jefferies Financial Group

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective lifted by analysts at Jefferies Financial Group from $58.00 to $71.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group’s price objective points to a potential upside of 32.03% from the stock’s current price.

A number of other analysts also recently issued reports on KNSA. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, April 21st. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the stock an “outperform” rating in a research report on Thursday, April 16th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Friday, April 17th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $58.43.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock traded up $10.17 during trading hours on Tuesday, reaching $53.78. 2,307,471 shares of the stock were exchanged, compared to its average volume of 688,927. The firm’s 50-day moving average is $45.94 and its 200-day moving average is $42.86. The company has a market cap of $4.12 billion, a price-to-earnings ratio of 72.24 and a beta of 0.06. Kiniksa Pharmaceuticals International has a 12 month low of $22.23 and a 12 month high of $53.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.06. The firm had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $207.12 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company’s revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.11 EPS. As a group, equities research analysts forecast that Kiniksa Pharmaceuticals International will post 1.09 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 7,278 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $50.01, for a total value of $363,972.78. Following the sale, the chief executive officer owned 7,278 shares in the company, valued at $363,972.78. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the transaction, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. This trade represents a 59.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 61,479 shares of company stock worth $2,832,812. Insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP raised its holdings in Kiniksa Pharmaceuticals International by 281.9% in the 3rd quarter. GSA Capital Partners LLP now owns 77,984 shares of the company’s stock valued at $3,028,000 after acquiring an additional 57,566 shares during the period. Fisher Asset Management LLC boosted its stake in Kiniksa Pharmaceuticals International by 176.1% in the 3rd quarter. Fisher Asset Management LLC now owns 282,288 shares of the company’s stock valued at $10,961,000 after purchasing an additional 180,029 shares during the period. Aberdeen Group plc bought a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $6,163,000. Essex Investment Management Co. LLC boosted its stake in Kiniksa Pharmaceuticals International by 44.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company’s stock valued at $9,603,000 after purchasing an additional 75,864 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in Kiniksa Pharmaceuticals International during the third quarter worth about $1,480,000. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.